PGRN Symposium at ASHG 2018 The Genomics of Drug Response from Discovery to Implementation

San Diego Convention Center Room 6A

Day 1 Agenda

Monday, October 15, 2018

Introductory Session	
1:00 – 1:15 pm	Welcome and Introductions Dan Roden (Vanderbilt University)
Session 1: The R Trials	ole of Human Genetics in Drug Development from Target Identification to Clinical
Moderators: Rock	helle Long (NIGMS) and Jean-Claude Marshall (Pfizer)
1:15 – 1:55 pm	Rare Variants and Drug Target Discovery Alan Shuldiner (Regeneron)
1:55 – 2:35 pm	Using GWAS and Sequence Data to Identify and Validate Drug Targets Matt Nelson (GSK)
2:35 – 3:15 pm	Presentation from the Industry Pharmacogenomics Working Group (I-PWG) Jean-Claude Marshall (Pfizer)
3:15 – 3:30 pm	Break
	enges and Opportunities in Pharmacogenetic Implementation n Shuldiner (Regeneron) and Henk-Jan Guchelaar (Leiden University)
3:30 – 4:10 pm	Collecting and Curating the Evidence for Pharmacogenetic Implementation: CPIC Mary Relling (St. Jude Children's Research Hospital)
4:10 – 4:50 pm	Implementation of Pre-emptive Pharmacogenomic Testing in the European Union: The U-PGx Consortium Henk-Jan Guchelaar (Leiden University)
4:50 – 5:30 pm	Implementation of Pharmacogenomic Testing for Minority/Special Populations Minoli Perera (Northwestern University)
5:30 – 5:45 pm	Closing Remarks
5:45 – 7:30 pm	Reception and Poster Session (Location: Sails Pavilion)

Day 2 Agenda

Tuesday, October 16, 2018

Session 3: Dual Genomes in Pharmacogenomics

Moderators: Ron Krauss (CHORI) and Kathy Giacomini (UCSF)

8:00 – 8:40 am The Microbiome and Pharmacogenomics

Peter Turnbaugh (UCSF)

8:40 – 9:20 am The Cancer Genome and Pharmacogenomics

Razelle Kurzrock (UCSD)

9:20 - 10:00 am Metabolome for Pharmacogenetics

Amalio Telenti (The Scripps Research Institute)

10:00 - 10:15 am Break

Session 4: Genomics and Precision Drug Therapy

Moderators: Joe Loscalzo (Harvard)

Panelists: Mary Relling (St. Jude Children's Research Hospital), George Patrinos (University of Patras), Charles Rotimi (NHGRI), Peter Turnbaugh (UCSF), Amalio Telenti (The Scripps Research Institute), Gert-Jan van Ommen (LUMC), Razelle Kurzrock (UCSD)

10:15 - 11:45 am Moderated Panel Discussion

11:45 – 1:00 pm Lunch (on your own)

Session 5: Pharmacogenomics: Rare Diseases and Rare Adverse Drug Reactions

Moderators: Munir Pirmohamed (University of Liverpool) and Jeffrey Kidd (University of Michigan)

1:00 – 1:10 pm Introductory Remarks

Dan Roden (Vanderbilt University)

Part 1: Drug Development for Rare Genetic Diseases

1:10 – 1:40 pm Overview and Rare Neurological Diseases

David Goldstein (Columbia)

1:40 – 2:10 pm Immune-Mediated Diseases

Robert Plenge (Celgene)

2:10 - 2:30 pm Break

Part 2: Immunopharmacogenomics

2:30 – 3:00 pm Immunopharmacogenomics and Adverse Drug Reactions

Munir Pirmohamed (University of Liverpool)

3:00 – 3:30 pm Mechanisms in Immune-Mediated Drug Reactions: Beyond HLA alleles

Elizabeth Phillips (Vanderbilt University Medical Center)

3:30 – 4:00 pm Panel Discussion on Rare Phenotypes and Immunopharmacogenomics and Closing Remarks